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The recognition of the antiangiogenic properties of taxanes provides a basis for novel therapeutic approaches. A prolonged exposure
to low drug concentrations has been proposed to be the most suitable approach to exploit the antiangiogenic potential of
cytotoxic agents. Such schedule is required to target preferentially slowly dividing endothelial cells. The protracted use of taxanes
could benefit from the availability of a taxane endowed with a favourable tolerability profile. Among compounds of a novel
series of C-seco taxanes, IDN 5390 was originally selected on the basis of its potent antimotility activity and poor cytotoxicity on
endothelial cells. The aim of the study was to investigate the preclinical pharmacologic profile of IDN 5390 in a variety
of human tumour xenografts, including ovarian and colon carcinoma and a glioblastoma. IDN 5390, delivered by s.c. injection, daily for
5 days per week, exhibited a high activity against all tumours investigated (tumour growth inhibition was always 485%) in the range
of well-tolerated doses. The maximum tolerated dose/injection (MTD), with no signs of systemic or local vesicant toxicity, was
120mgkg
 1. In contrast, paclitaxel, delivered according to the same schedule, exhibited a variable antitumour efficacy associated with
a substantial local toxicity (MTD¼10mgkg
 1). Considering the remarkable efficacy of IDN 5390 delivered s.c. by protracted
treatment schedule, the oral route of administration was further investigated, as the most suitable for daily treatment. Indeed, a good
bioavailability of oral IDN 5390 was found. Oral IDN 5390 maintained a substantial efficacy against human tumour xenografts,
including paclitaxel-resistant tumours, without loss of potency with respect to s.c. administration. In conclusion, the therapeutic
advantages of IDN 5390, over paclitaxel, in protracted daily treatment schedules are represented by the oral efficacy and the high
tolerability, which are favourable features to exploit the antiangiogenic potential and to design combinations with other
effective agents.
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In the field of antineoplastic chemotherapy, taxanes (paclitaxel
and docetaxel) represent an important class of compounds,
with broad activity in solid tumours (Rowinsky, 1997).
Taxanes are tubulin-binding agents, characterised by a unique
mechanism of action, that is, microtubule stabilisation
(Horwitz et al, 1993), in contrast to microtubule depolymerisation
promoted by vinca alkaloids and colchicine (Jordan et al,
1991).
Microtubule-destabilising agents have been recently investigated
as antivascular compounds (Iyer et al, 1998; Blakey et al, 2002),
and an antiangiogenic potential has been reported for
paclitaxel (PTX) and docetaxel (Belotti et al, 1996; Klauber et al,
1997; Lau et al, 1999; Schimming et al, 1999; Sweeney et al, 2001;
Cassinelli et al, 2002). The antiangiogenic activity of PTX
has been ascribed mainly to its ability to inhibit endothelial cell
motility, rather than proliferation (Belotti et al, 1996) and to
downregulate angiogenesis-related growth factors (Cassinelli et al,
2002). In order to target preferentially endothelial cells in in vivo
models, a dosing schedule of the drug by short intervals and no
interruption has been indicated as effective, in contrast to
conventional schedules (i.e. maximum tolerated doses with
extended resting periods) (Hanahan et al, 2000). By delivering
conventional agents according to such ‘an antiangiogenic sche-
dule’, a strong antitumour efficacy was achieved, even against
chemoresistant tumours (Browder et al, 2000; Klement et al, 2000).
The protracted use of cytotoxic agents may be hampered by a
relevant toxicity. To identify novel molecules endowed with a
favourable profile of tolerability in protracted treatment schedules,
a series of taxane analogues was synthesised (Appendino et al,
1997; Distefano et al, 1998), and the C-seco taxane IDN 5390 was
selected for preclinical development (Pratesi et al, 2002;
Taraboletti et al, 2002).
The aim of the study was to further characterise the biological
properties of IDN 5390 and to investigate its preclinical
pharmacological profile in a series of human tumour xenografts,
including PTX-resistant tumours. The oral or s.c. daily adminis-
tration of IDN 5390 was highly effective against all the tumour
models investigated.
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sMATERIALS AND METHODS
Drugs
IDN 5390 (13-(N-Boc-b-isobutylisoserinyl)-10b-dehydro-C-seco-
10-deacetylbaccatin III) and PTX (Figure 1), used as reference
drug, were provided by Indena S.p.a. (Milan, Italy).
In vitro studies
Drugs were dissolved in DMSO and freshly diluted in medium
before use. The antiproliferative activity was evaluated on
A2780 (human ovarian carcinoma) and its derived drug-resistant
cell lines (A2780/DX, A2780/DDP), IGROV-1/Pt1 (human ovarian
carcinoma), GBM (human glioblastoma) and MX-1 (human
mammary carcinoma). All cell lines, except MX-1, were main-
tained in RPMI 1640 (Bio-Whittaker, Verviers, Belgium)
supplemented with 10% fetal calf serum (Life Technologies,
Gaithersburg, MD, USA). MX-1 cells were maintained in
McCoy’s medium (Life Technologies, Gaithersburg, MD, USA)
supplemented with 10% fetal calf serum. For experiments, all cell
lines were seeded into six-well plates in duplicate and treated, 24 or
72h (only MX-1 cells) after seeding, with solvent or different
concentrations of taxanes. Adherent cells were counted 72h after
the beginning of treatment, by a cell counter (Coulter Electronics,
Luton, UK) or detected by the Sulforhodamine B colorimetric
assay (only GBM cells). The IC50 was defined as the drug
concentration causing a 50% decrease in cell number over that
of untreated controls.
For cell cycle analysis, after 24h of treatment, GBM adherent
cells were trypsinised and fixed in 70% ethanol. Cell cycle
perturbations were measured on propidium iodide-stained cells
by flow cytometry (Supino et al, 2001).
For tubulin polymerisation assay, IGROV-1/Pt1 cells were
treated with PTX or IDN 5390 at the indicated concentrations
for 24h. Cells were then processed as previously described
(Cassinelli et al, 2001) in order to separate cellular fractions
containing soluble cytosolic or polymerised cytoskeletal tubulin.
Samples were electrophoresed by sodium dodecyl sulphate (SDS)–
PAGE (10% resolving gel and 3% stacking gel) and blotted onto
nitrocellulose membranes. The distribution of tubulin was
analysed by immunoblotting, using a rabbit polyclonal antitubulin
antibody (BioMakor, Revohot, Israel).
To investigate taxane-induced modulation of Raf-1 and Bcl-2,
IGROV-1/Pt1 cells were exposed to the indicated concentrations of
drug for 24h. Expression of vascular endothelial growth
factor (VEGF) and basic fibroblast growth factor (bFGF)
was detected in GMB cells after 72h of drug exposure.
Floating and adherent cells were collected and whole-cell
extracts were prepared by lysing cells in SDS sample buffer
(62.5mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 5%
b-mercaptoethanol, 0.001% bromophenol blue) with 1mM
PMSF, 10mgml
 1 pepstatin, 100kIU aprotinin, 12.5mgml
 1
leupeptin, 1mM sodium orthovanadate and 1mM sodium molyb-
date. Equal amounts of proteins were fractionated by SDS–PAGE
and blotted on nitrocellulose sheets. Filters were incubated with
mouse monoclonal anti-Bcl-2 antibody or with the rabbit
polyclonal antibodies anti-Raf-1, anti-VEGF or anti-bFGF (Santa
Cruz Biotechnology, CA, USA). Immunoreactive bands were
visualised by the Pierce Super Signal system (Pierce, Rockford,
IL, USA).
In vivo studies
All the experiments were carried out using female athymic nude
CD-1 mice, 8–11 weeks old (Charles River, Calco, Italy). The mice
were maintained in laminar flow rooms with constant temperature
and humidity. Experimental protocols were approved by the Ethics
Committee for Animal Experimentation of the Istituto Nazionale
per lo Studio e la Cura dei Tumori (Milan, Italy) according to the
United Kingdom Coordinating Committee on Cancer Research
Guidelines (Workman et al, 1998).
Taxanes were dissolved by adding absolute ethanol and
Cremophor ELP (both 5% of the final volume), in that sequence,
on a magnetic stirrer. Details of the procedure have been
already reported (Polizzi et al, 1999). After dilution, the drug
solutions were always kept on ice. For the oral delivery of
IDN 5390 a different solvent was used, that is, Polysorbate 80 in
0.9% NaCl, because it allowed a more favourable relative drug
bioavailability than Cremophor ELP in the mouse (data not
shown), and is more appropriate for clinical development.
A stock solution of IDN 5390 in Polysorbate 80 was provided
by Indena S.p.a. (Milano, Italy) and, just before use, it was
diluted, by slowly adding 0.9% NaCl and occasionally stirring
the solution (final Polysorbate 80: 10%, vv
 1). With such
procedures, drug solutions of 3.6 and 9mgml
 1 were prepared
for PTX and IDN 5390, respectively, corresponding to 36 and
90mgkg
 1, for an administration volume of 10mlkg
 1 of body
weight (BW). When higher doses were to be given, larger volumes
were injected.
The human tumour lines investigated in the study were selected
for their variable degrees of sensitivity to PTX, that is, highly
sensitive, MX-1 mammary and A2780/DDP ovarian carcinomas,
and resistant, IGROV-1 (natural resistance) and INT.ACP/PTX
(acquired resistance) ovarian carcinomas. The INT.ACP/PTX
tumour line was derived from a single A2780/DDP tumour that
did not respond to PTX treatment. Tumour lines were maintained
in vivo by successive s.c. transplants of tumour fragments in
animal flanks.
For chemotherapy experiments, tumour fragments (about
2 2 2 mm), obtained from tumour lines, were implanted s.c.
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IDN 5390 Paclitaxel
Figure 1 Chemical structure of paclitaxel and IDN 5390.
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sEach control or drug-treated group included five or six mice
bearing bilateral s.c. tumours. Tumours were implanted on day 0,
and tumour growth was followed by biweekly measurements of
tumour diameters with a vernier caliper. Tumour weight
(TW) was calculated according to the formula: TW (mg)¼tumour
volume (mm
3)¼d
2 D/2, where d and D are the shortest and the
longest diameter, respectively. Different treatment routes (i.v., s.c.
or p.o.) and schedules (daily or intermittent) were investigated.
Treatment started at different times after tumour implant
(see Results). Control mice were injected with the solvent
solution.
The efficacy of the drugs was assessed as follows: (a) TWI% in
drug-treated vs control mice expressed as: TWI%¼100   (mean
TW treated/mean TW control  100), evaluated during or after
drug treatment; (b) Log10 cell kill (LCK) calculated by the formula:
LCK¼(T C)/3.32 DT, where T and C are the mean times
(in days) required for treated and control tumours, respectively, to
reach a predetermined weight and DT is tumour doubling time;
an LCK value greater than 1 is indicative of an active compound;
and (c) complete response (CR), that is, no evidence of
tumour at the end of experiments. Experimental groups were
eliminated when mean TW was about 1.570.5g, or after
100 days.
For statistical analysis, tumour weights in different groups
of treated mice were compared on day of TWI% evaluation,
by Student’s t-test (two-tailed). Pp0.05 was considered significant.
The tolerability of the compound was assessed in tumour-
bearing mice as follows: (a) lethal toxicity, that is, any death in
treated mice without or with small (p300mg) tumours, or
occurring before any control death; (b) body weight loss %
(BWL%)¼100–(BW on day x/BW on day 1 100), where x
represents a day after or during the treatment period. The maximal
BWL values are reported; and (c) vesicant toxicity defined as the
appearance of ulcers and/or inflammation at the injection site
where the drugs were delivered s.c.
Pharmacokinetic study
In order to assess the bioavailability of IDN 5390, a pharmaco-
kinetic study was performed in female CDF1 mice (Charles
River Italia, Calco, Italy). IDN 5390, formulated in Polysorbate
80 and diluted in 0.9% NaCl solution, immediately before treatment,
was administered p.o. or i.v. at the dose of 120mgkg
 1. Blood
samples were taken (four mice per group) from the retro-orbital
plexus, under diethylether anaesthesia at 5, 15 and 30 min and at
1, 2 and 4h.
IDN 5390 levels were determined in plasma according to the
high-performance liquid chromatography (HPLC) method of
Zaffaroni et al (2002). Briefly, plasma samples (0.4ml) were
spiked with 1mg IDN 5517, as internal standard, and with 0.7ml of
0.2 M ammonium acetate buffer, pH 4.5, and extracted by solid-
phase extraction on a cyano cartridge (Waters, Millford, MA,
USA). HPLC analyses were carried out on a Symmetry C18 column
(3.5mm, 4.6 150mm; Waters, London, UK), with UV detection of
the analytes at 227nm. The lower limit of quantitation was of
50ngml
 1.
Pharmacokinetic parameters were calculated by using a
nonlinear fitting program (Sacchi-Landriani et al, 1983). The
experimental areas under the concentration–time curve (AUCexp)
of IDN 5390 were calculated by the trapezoidal rule. Extrapolations
to infinity (AUCinf) were obtained by dividing the concentration at
the last experimental points by the elimination constant (Ke). The
terminal half-lives (T1/2) were calculated using the formula
T1/2¼0.693/Ke. Clearance (Clp) and volume of distribution (Vd)
were obtained from the following relation: Clp¼Dose/AUCext and
Vd¼Clp/Ke, respectively. The bioavailability (F) was derived from
the ratio: F¼AUCp.o./AUCi.v. 100.
RESULTS
Cellular pharmacology
In a panel of human tumour cell lines, IDN 5390 exhibited a
modest reduction of cytotoxicity (2–3-fold) as compared to PTX
(Table 1). In A2780/DX cells (which express a typical MDR
phenotype mediated by P-gp), both agents exhibited very low
cytotoxicity, thus suggesting that both agents are substrates for
P-gp.
Cell cycle distribution analysis of GBM cells treated with
equitoxic concentrations (IC50) of the two taxanes, showed a
similar increase of cells in G2/M phase 24h after treatment
(Figure 2).
Based on the observed interference on cell cycle progression,
comparison among IDN 5390 and PTX for the ability to induce
tubulin polymerisation and phosphorylation of Bcl-2 and Raf-1
was performed, after 24h exposure. According to the lower
antiproliferative potency, IDN 5390 was less effective than the
parent drug in promoting tubulin polymerisation at the same
concentration (100ngml
 1) in IGROV-1/Pt cells. However, a
comparable extent of tubulin polymerisation was found in cells
treated with equitoxic concentrations (IC80) of IDN 5390 or PTX
(300 and 100ngml
 1, respectively). Again, the analysis of Bcl-2
and Raf-1 phosphorylation, events associated with taxane-induced
mitotic arrest (Ling et al, 1998), indicated comparable levels of
phosphorylation induced by equitoxic concentrations of the two
drugs (Figure 3).
The effects of the C-seco derivative on the expression of the two
main angiogenic factors, VEGF and bFGF, were examined in GBM
cells. After 72h of exposure to 40ngml
 1 IDN 5390 (correspond-
ing to its IC80), both angiogenic factors were downregulated, the
effect on VEGF being more pronounced (Figure 4). The equitoxic
concentration of PTX (17ngml
 1) showed similar effects.
In vivo studies
The optimal PTX regimen for i.v. treatment of human tumours
xenografted in mice is the intermittent administration every fourth
day (q4d) for four times, with the MTD 54mgkg
 1inj
 1 (inj ¼
injection) (Polizzi et al, 1999). Based on the relative cytotoxic
potency observed in cell systems, doses 2–3-fold higher were
delivered for i.v. IDN 5390 (i.e. 90 and 120mgkg
 1), q4d 4 times,
to mice bearing the A2780/DDP human tumour xenograft
(Table 2). In contrast to PTX, the analogue resulted quite inactive.
Thus, an alternative schedule with a more frequent treatment
(daily for 5days per week, qd 5/w) was investigated. The s.c.
route was preferred to the i.v., as it was more suitable for
protracted daily treatments in mice. According to such schedule,
Table 1 Antiproliferative activity of taxanes
IC50 (ng/ml)
a
Cell line Tumour type IDN 5390 PTX
A2780 Ovarian carcinoma 2370.4 8.170.9
A2780/DX Ovarian carcinoma 334 313
A2780/DDP Ovarian carcinoma 31.875.5 11.871.4
IGROV-1/Pt Ovarian carcinoma 61.574.5 36.175.5
MX-1 Mammary carcinoma 34.577.8 12.772.7
GBM Glioblastoma 12.972.4 3.271.2
aCells were treated for 72h. The antiproliferative effect was evaluated by the
Sulforhodamine B colorimetric assay for the GBM cell line or by cell counting for the
other cell lines. IC50: drug concentration inhibiting 50% of cell proliferation
(mean7s.d., from three different experiments).
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(120mgkg
 1inj
 1) was as active as PTX at its best regimen. In
contrast, daily PTX was much less effective at the dose of
10mgkg
 1inj
 1, which was the maximal tolerated as a conse-
quence of the local vesicant toxicity. Indeed, higher PTX doses or
more protracted treatment resulted in severe ulcerations in most
mice. This side effect was not observed in IDN 5390-treated mice.
Based on these findings, the daily schedule was chosen for
further experiments with IDN 5390. Against the MX-1 mammary
carcinoma, which is highly responsive to PTX, various dose levels
of IDN 5390 were investigated by the s.c. route, with the treatment
beginning the day after tumour inoculum (Table 3). After 3 weeks
of treatment (weekend excluded), all doses were highly effective in
inhibiting tumour growth (TWI always 480%) and comparable
effects were achieved with 90 and 120mgkg
 1. In spite of the
prolonged treatment (3 weeks), the dose of 120mgkg
 1inj
 1 was
well tolerated and devoid of local vesicant toxicity. The dose level
of 150mgkg
 1 resulted highly toxic (three out of five lethal
toxicity) after only four administrations. Considering the im-
pressive efficacy of the protracted treatment schedules with IDN
5390 s.c., the oral route of administration was investigated, as the
most suitable for daily treatment. The dose level of 120mgkg
 1
was highly effective in inhibiting tumour growth even with oral
administration.
The complete lack of any toxic effect suggested the possibility to
further increase the frequency with oral treatment. MX-1 tumour-
bearing mice were treated p.o. with various (i.e. 30, 60 and
90mgkg
 1inj
 1) dose levels of IDN 5390, twice a day (2 ),
starting when tumours averaged 100mg (Figure 5). All doses
resulted well tolerated. The low dose, 30mgkg
 1, was not very
effective. The daily dose of 120mgkg
 1 for 3 weeks was very
effective when delivered either by a single or by two fractionated
treatments (2 60mgkg
 1), and TWI and LCK values of the two
groups were not significantly different. The most relevant result of
the study was the impressive efficacy achieved by the treatment
with the dose of 2 90mgkg
 1. The dose was completely tolerated
(11% max BWL, no lethal toxicity) for up to 5 weeks for a total of
50 treatments, that is a cumulative dose of 4500mgkg
 1. The
activity was extremely high and six out of 10 tumours exhibited CR
at the end of the experiment (100 days).
The efficacy of the daily IDN 5390 was tested against two PTX-
resistant ovarian human tumour xenografts, that is, the IGROV-1
Equivalent concentration
C
S P
PTX
S P
IDN 5390
S P
Equitoxic concentration
C
S P
PTX
S P
IDN 5390
S P
Tubulin
C PTX
IDN 5390
C PTX
IDN 5390
Raf-1
Bcl-1
Figure 3 Effects of taxanes on tubulin polymerisation and on Raf-1/Bcl-2 phosphorylation in IGROV-1/Pt1 cells. Cells were treated for 24h at equivalent
(100ngml
 1) or equitoxic (IC80) concentrations (PTX, 100ngml
 1; IDN 5390, 300ngml
 1). Cellular fractions containing soluble cytosolic (S) or
polymerised cytoskeletal (P) tubulin were subjected to immunoblotting with antitubulin antibodies. Whole-cell extracts were processed for immunoblotting
with anti-Raf-1 or anti-Bcl-2 antibodies. The phosphorylated forms of Raf-1 and Bcl-2 are indicated by arrows.
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N
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Figure 2 Cell cycle distribution in GBM cells treated with taxanes at the IC50. After 24h of treatment, cells were harvested, fixed, stained with propidium
iodide and analysed by flow cytometry. One experiment representative of two is reported.
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s(natural resistance, likely related to P-gp expression) and the INT-
ACP/PTX (acquired resistance to both cisplatin and PTX). The oral
dose of 120mgkg
 1, daily for 3 weeks (weekend excluded), was
well tolerated and active against the IGROV-1 tumour, whereas
PTX at its best regimen was inactive, achieving a TWI of 30%
(Table 4). Against the INT-ACP/PTX human tumour xenograft, the
dose of 2 90mgkg
 1 (twice a day) showed only a partial efficacy,
whereas a strong efficacy (96% TWI) was achieved by a daily
injection of 180mgkg
 1. However, such dose was toxic after 2
weeks of treatment. Although highly active (87% TWI), the
treatment with two injections per day of 120mgkg
 1 for 2 weeks
was not tolerated (one toxic death and 15% BWL). Against the
INT-ACP/PTX tumour, PTX was inactive (TWI o50%) when
administered either i.v. (best regimen) or s.c. (daily treatment)
(Table 4).
Pharmacokinetic study
Figure 6 shows the plasma levels of IDN 5390 determined
in CDF1 mice after p.o. or i.v. treatment with 120mgkg
 1
of the drug, and summarises the main derived pharmacokinetic
parameters. Following i.v. administration, the drug was
rapidly distributed and eliminated with a terminal half-life of
54min. After oral treatment, IDN 5390 was rapidly absorbed,
achieving a peak plasma concentration of 25.0mgml
 1 at
30min. As observed after the i.v. administration, the drug was
rapidly eliminated with a terminal half-life of 42min. A
comparison of the AUCs obtained after oral and i.v. admini-
stration indicated that IDN 5390 possessed a bioavailability of
27.3%.
Table 2 Antitumour activity of taxanes on A2780/DDP ovarian tumour xenograft
Treatment
Drug Route Schedule
a Dose (mgkg
 1) Max TWI%
b (days)
c LCK
d (1g) Max BWL
e (%) Tox/Tot
f
IDN 5390 i.v. q4d 4 90 17 (18) 0.2 0 0/5
i.v. q4d 4 120 46 (18) 0.3 3 0/5
PTX i.v. q4d 4 54 94 (18) 2.1 5 0/5
IDN 5390 s.c. qd 5/w 2w 120 92 (27) 1.8 2.5 0/5
PTX s.c qd 5/w 2w 10 62 (27) 0.2 0 0/5
aDrugs were delivered every fourth day for four doses (q4d 4) or daily (qd) for five doses each week for 2 weeks, starting when mean tumour weight was about
100mg.
bOptimal tumour weight inhibition (%) in treated vs control mice. Values in parentheses represent the day of observation.
cDays are always calculated from
the day of tumour inoculum (day 0).
dLog10 cell kill in treated tumours, calculated to a mean TW of 1g.
eMaximum body weight loss (%).
fNumber of toxic death/
total number of mice in the group.
Table 3 Antitumour activity of taxanes on MX-1 mammary tumour xenograft
Treatment
Drug Route Schedule
a Dose (mgkg
 1) Max TWI%
b (days)
c LCK
d (1g) Max BWL
e (%) Tox/Tot
f
IDN 5390 s.c. qd 4–5/w 3w 60 83(29) 1.4 3 0/3
s.c. qd 4–5/w 3w 90 97(29) 2.7 3.5 0/5
s.c. qd 4–5/w 3w 120 93–96*(25) 1.7–3.1 6–7.5 1/10
s.c. qd 4 150 N.D. N.D. N.D. 3/5
p.o. qd 4–5/w 3w 120 82(25) 1.1 5 0/5
PTX i.v. q4d 4 54 100(45) >4.3 8 0/4
aDrugs were delivered every fourth day for four doses (q4d 4) or daily for four or five doses each week for 1–3 weeks, from day 1. See footnotes b–f of Table 2.
*Po0.05 vs p.o.-treated tumours, by Student’s t-test.
C PTX
IDN 5390
bFGF
VEGF
Actin
Figure 4 Effects of taxanes on VEGF and bFbF expression in GBM cells.
Cells were treated for 72h at equitoxic (IC80) concentrations (PTX,
17ngml
 1; IDN 5390, 40ngml
 1). Whole-cell extracts were processed for
immunoblotting with anti-VEGF or anti-bFGF antibodies.
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sDISCUSSION
The results presented in the paper clearly indicated that the novel
C-seco derivative IDN 5390, was well tolerated in protracted
multiple dose regimens. The excellent tolerability of IDN 5390 was
an unexpected finding, since in in vitro systems the derivative is
only slightly less cytotoxic than PTX and the effects on tubulin
polymerisation are comparable to those of PTX at equitoxic
concentrations. Again, the effects of IDN 5390 and PTX on
pathways involving Bcl-2 and Raf phosphorylation were compar-
able, thus suggesting a common mechanism of action at the
cellular level, with tubulin as the primary cellular target and
activation of biochemical pathways that typically characterise the
cellular response to microtubule damage (Cassinelli et al, 2001;
Lanzi et al, 2001).
The most important finding of the present study was the
peculiar pharmacological behaviour of IDN 5390 in in vivo
systems, Indeed, IDN 5390 delivered according to an intermittent
schedule, considered as an optimal regimen for PTX in preclinical
models (Polizzi et al, 1999), was inactive against a responsive
human ovarian carcinoma xenograft, the A2780/DDP, even at
doses higher than those of PTX. However, the growth of the same
tumour was strongly inhibited by IDN 5390 when the compound
was delivered more frequently. The daily administration of IDN
Table 4 Antitumour activity of taxanes on PTX-resistant ovarian tumour xenografts
Treatment
Drug Route Schedule
a Dose (mgkg
 1)T W I %
b (day 27)
c LCK
d (1g) Max BWL
e (%) Tox/Tot
f
IGROV-1
IDN 5390 p.o. qd 5/w 3w 120 73 2.2 13 0/4
PTX i.v. q4d 4 54 30 0.2 17 1/5
INT.ACP/PTX
IDN 5390 p.o. qd 5/w 3w 2 90 66 0.8 9 0/6
p.o. qd 5/w 2w 2 120 87 1.4 15 1/5
p.o. qd 5/w 2w 180 96* 1.9 10 2/5
PTX s.c. qd 5/w 2w 1.25 12 0 0 0/4
s.c. qd 5/w 2w 2.5 26 0 0 0/5
s.c. qd 5/w 2w 5  10  0.2 0 0/5
s.c. qd 5/w 2w 10 43 0.1 2 0/5
i.v. q4d 3 54 46 0.3 14.5 1/5
aDrugs were delivered: every fourth day for 3/4 doses (q4d 3/4); once daily (qd) or twice (2 ) for four or five doses each week, for 2 or 3 weeks, starting when
mean tumour weight was about 75–100mg. See footnotes b–f of Table 2. *Po0.05 (by Student’s t-test) vs 2 90mgkg
 1day
 1 treated mice.
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Figure 5 Growth curves of MX-1 human mammary carcinoma xenografted in nude mice after treatment with IDN 5390, qd 5d/w: (K)2 30mgkg
 1
(qd 3w), p.o.; (’)2 60mgkg
 1 (qd 3w), p.o., (m)2 90mgkg
 1 (qd 5w), p.o.; (.) 120mgkg
 1 (qd 3w), p.o.; (*) 120mgkg
 1 (qd 3w), s.c.;
( ) untreated control. Inset: number of complete response/total number of tumours.
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xenografts investigated, including PTX-resistant tumours. Inter-
estingly, the analogue was effective (TWI470%, LCK: 2.2) even
against the IGROV-1 ovarian tumour xenograft, which is naturally
resistant to PTX possibly because of Pgp 170 expression (De
Cesare et al, 2001). Since in cell systems, IDN 5390 was unable to
overcome Pgp-mediated resistance (Table 1), mechanisms other
than a direct cytotoxicity against tumour cells seem to contribute
to its antitumour efficacy in vivo.
The unique profile of tolerability and antitumour activity of IDN
5390 is likely related to still unrecognised changes in drug–cellular
interactions that may be critical in modulating the toxic and
therapeutic effects of taxanes. The opening of the ring at C-7 and
C-8 is consistent with the reduction of cytotoxic potency;
however, such modulation does not account for the tolerability
of substantially higher dose levels than with PTX. When
delivered by daily s.c. administration, the MTD for a prolonged
period (at least 3 weeks) was 120mgkg
 1 per treatment.
The same dose level was tolerated and active even when delivered
p.o., thus suggesting an adequate bioavailability of the compound.
At the dose level investigated in the study, about 30% of
IDN 5390 was absorbed after oral administration. Indeed, the
pharmacokinetic studies indicated a rapid absorption, distribution
and elimination (T1/2o1h) of IDN 5390 in mice. Accordingly,
when two treatments per day (2 90mgkg
 1) were delivered p.o.,
again no toxic effects were observed in treated mice up to at least 5
weeks (50 treatments), indicating the absence of drug accumula-
tion. The good efficacy of the oral treatment represents a
pharmacological advantage of IDN 5390 over PTX, which is
poorly absorbed by such administration route (Sparreboom et al,
1997).
In addition to the lack of systemic toxicity, no symptoms of
neurotoxicity were evident in IDN 5390-treated mice. Moreover,
no local vesicant toxicity was observed with the s.c. delivery of IDN
5390 at any dose. In contrast, local toxicity was frequent and
persistent with PTX s.c., and the maximum dose level tolerated was
10mgkg
 1day
 1 for 2 weeks. In contrast to PTX, which exhibited
a variable activity against the examined tumour models with the
daily treatment, the efficacy of IDN 5390 was consistently high in
all tumours. Such a pharmacological profile suggests a mechanism
of antitumour activity in part different from that of PTX. A
plausible explanation for the unusual behaviour of IDN 5390 could
be a contribution of antiangiogenic properties of the C-seco
derivative to the therapeutic efficacy. The ability of IDN 5390 to
downregulate the expression of angiogenic factors has been
documented in our study (Figure 4). Very high dose levels could
be safely delivered for repeated weeks, possibly allowing a strong
and prolonged inhibitory effect of angiogenic growth factors. It
seems likely that such property, in addition to the unique ability to
inhibit endothelial cell motility (Taraboletti et al, 2002), might
contribute to the antitumour effect of IDN 5390 in vivo. Moreover,
prolonged chronic treatment schedules have been reported as the
most suitable for exploiting the antiangiogenic effect of cytotoxic
drugs in in vivo systems (Browder et al, 2000; Hanahan et al, 2000;
Klement et al, 2000). Preclinical and clinical experiences with PTX
support the hypothesis (Miller et al, 2001) and such schedule
resulted as the best one for the antitumour efficacy of IDN 5390. A
relation between angiogenesis and tumour growth is complex in in
vivo systems (Hahnfeldt et al, 1999) and will be addressed in a
further study.
In conclusion, the novel taxane analogue IDN 5390 is highly
effective in a panel of human tumour xenografts, including PTX-
resistant tumours. The discrepancy between its in vitro and in vivo
potency, as well as the requirement for frequent and protracted
administration for drug efficacy seem to indicate a host-mediated
contribution, more than a direct cytotoxic effect, in its antitumour
efficacy. Moreover, the unexpected tolerability and the good
bioavailability indicate a peculiar pharmacological behaviour and
the interest for further development of the compound adminis-
tered orally.
ACKNOWLEDGEMENTS
This work was partially supported by the Associazione Italiana
Ricerca sul Cancro, Milan, by the Ministero della Sanita `, Rome and
by the Consiglio Nazionale delle Ricerche, Rome, Italy.
We thank Ms Monica Tortoreto for her technical assistance and
Ms Laura Zanesi for her editorial assistance.
REFERENCES
Appendino G, Danieli B, Jakupoviv J, Belloro E, Scambia G, Bombardelli E
(1997) Synthesis and evaluation of C-seco paclitaxel analogues. Tetra-
hedron Lett 38: 4273
Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R,
Taraboletti G (1996) The microtubule-affecting drug paclitaxel has
antiangiogenic activity. Clin Cancer Res 2: 1843–1849
1000
100
I
D
N
 
5
3
9
0
 
(

g
 
m
l
−
1
)
10
1
0.1
0.0 0.5 1.0 1.5 2.0
Time (h)
Dose (mg kg
−1)
Cmax (g ml
−1)
Tmax (min)
AUCexp (g ml
−1 h)
AUCinf (g ml
−1 h)
T ½ (min)
Clp(l kg
−1 h)
Vd (l kg
−1 h)
2.5 3.0 3.5 4.0
120
160.9
5
125.4
128.4
54
0.93
0.21
120
25
30
34.4
35.1
42
-
-
Figure 6 Pharmacokinetics profile of IDN 5390 in CDF1 mice.
Comparison of drug plasma levels after treatment with 120mgkg
 1 i.v.
(m) or p.o. (K). Means7s.d. are reported from four mice per group. Inset:
main parameters.
IDN 5390: an oral taxane for protracted schedules
G Pratesi et al
971
British Journal of Cancer (2003) 88(6), 965–972 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sBlakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE,
Ryan AJ (2002) Antitumor activity of the novel vascular targeting agent
ZD6126 in a panel of tumor models. Clin Cancer Res 8: 1974–1983
Browder T, Butterfield CE, Kralling BM, Shi B, Marshall B, O’Reilly M
Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves
efficacy against experimental drug-resistant cancer. Cancer Res 60:
1878–1886
Cassinelli G, Lanzi C, Supino R, Pratesi G, Zuco V, Laccabue D, Cuccuru G,
Bombardelli E, Zunino F (2002) Cellular bases of the antitumor activity
of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory
prostate cancer. Clin Cancer Res 8: 2647–2654
Cassinelli G, Supino R, Perego P, Polizzi D, Lanzi C, Pratesi G, Zunino F
(2001) A role for loss of p53 function in sensitivity of ovarian carcinoma
cells to taxanes. Int J Cancer 92: 738–747
De Cesare M, Pratesi G, Perego P, Carenini N, Tinelli S, Merlini L, Penco S,
Pisano C, Bucci F, Vesci L, Pace S, Capocasa F, Carminati P, Zunino F
(2001) Potent antitumor activity and improved pharmacological profile
of ST 1481, a novel 7-substituted camptothecin. Cancer Res 61: 7189–
7195
Distefano M, Scambia G, Ferlini C, Gallo R, De Vincenzo R, Filippini P,
Riva A, Bombardelli E, Mancuso S (1998) Antitumor activity of paclitaxel
(taxol) analogues on MDR-positive human cancer cells. Anti-Cancer
Drug Design 13: 489–499
Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L (1999) Tumor development
under angiogenic signaling: a dynamical theory of tumor growth, treat-
ment response, and postvascular dormancy. Cancer Res 59: 4770–4775
Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly:
metronomic dosing of cytotoxic drugs can target tumor angiogenesis in
mice. J Clin Invest 105: 1045–1047
Horwitz SB, Cohen D, Rao S, Ringel I, Shen H-J, Yang C-PH (1993) Taxol:
mechanisms of action and resistance. J Natl Cancer Inst Monogr 15:
55–61
Iyer S, Chaplin DJ, Rosenthal DS, Boulares AH, Li LY, Smulson ME (1998)
Induction of apoptosis in proliferating human endothelial cells by the
tumour-specific antiangiogenesis agent combretastatin A-4. Cancer Res
58: 4510–4514
Jordan MA, Thrower D, Wilson L (1991) Mechanism of inhibition of cell
proliferation by vinca alkaloids. Cancer Res 51: 2212–2222
Klauber N, Parangi S, Flynn E, Hamel E, D’Amato RJ (1997) Inhibition of
angiogenesis and breast cancer in mice by the microtubule inhibitors 2-
methoxyestradiol and Taxol. Cancer Res 57: 81–86
Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel
RS (2000) Continuous low-dose therapy with vinblastine and VEGF
receptor-2 antibody induces sustained tumor regression without overt
toxicity. J Clin Invest 105: R15–R24
Lanzi C, Cassinelli G, Cuccuru G, Supino R, Zuco V, Ferlini C, Scambia G,
Zunino F (2001) Cell cycle checkpoint efficiency and cellular response to
paclitaxel in prostate cancer cells. Prostate 48: 254–264
Lau DH, Xue L, Young LJ, Burke PA, Cheung AT (1999) Paclitaxel (Taxol):
an inhibitor of angiogenesis in a highly vascularized transgenic breast
cancer. Cancer Biother Radiopharm 14: 31–36
Ling Y-H, Tornos C, Perez-Soler R (1998) Phosphorylation of Bcl-2 is a
marker of M phase events and not a determinant of apopstosis. J Biol
Chem 273: 18984–18991
Miller KD, Sweeney CJ, Sledge GW (2001) Redefining the target:
chemotherapeutics as antiangiogenics. J Clin Oncol 19: 1195–1206
Polizzi D, Pratesi G, Tortoreto M, Supino R, Riva A, Bombardelli E, Zunino
F (1999) A novel taxane with improved tolerability and therapeutic
activity in a panel of human tumour xenografts. Cancer Res 59: 1036–
1040
Pratesi G, Laccabue D, Cassinelli G, Lanzi C, Riva A, Morazzoni P,
Bombardelli E, Zunino F (2002) Preclinical profile of antitumour activity
of a novel taxane with a good tolerability in protracted therapeutic
regimens. Proc Am Assoc Cancer Res 43: 790
Rowinsky EK (1997) The development and clinical utility of the taxane
class of antimicrotubule chemotherapy agents. Annu Rev Med 48:
353–374
Sacchi-Landriani G, Guardabasso V, Rocchetti M (1983) NL-FIT: a
computer program for non linear fitting. Comput Programs Biomed 16:
35–42
Schimming R, Hunter NR, Mason KA, Milas L (1999) Inhibition of tumour
neo-angiogenesis and induction of apoptosis as properties of docetaxel
(taxotere). Mund Kiefer Gesichtschir 3: 210–212
Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, Maijer
DKF, Borst P, Nooijen WJ, Beijnen JH, Van Tellingen O (1997) Limited
oral bioavailability and active epithelial excretion of paclitaxel (Taxol)
caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94:
2031–2035
Supino R, Perego P, Gatti L, Caserini C, Leonetti C, Colantuono M, Zuco V,
Carenini N, Zupi G, Zunino F (2001) A role for c-myc in DNA damage-
induced apoptosis in a human p53-mutant small cell lung cancer cell
line. Eur J Cancer 37: 2247–2256
Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J, Sledge Jr
GW (2001) The antiangiogenic property of docetaxel is synergistic with a
recombinant humanized monoclonal antibody against vascular endothe-
lial growth factor or 2-methoxyestradiol but antagonized by endothelial
growth factors. Cancer Res 61: 3369–3372
Taraboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, Borsotti
P, Roccabianca P, Scanziani E, Nicoletti MI, Bombardelli E, Morazzoni P,
Riva A, Giavazzi R (2002) Antiangiogenic and antitumor activity of IDN
5390, a new taxane derivative. Clin Cancer Res 8: 1182–1188
Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J,
Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J
(1998) United Kingdom Coordinating Committee on Cancer Research
(UKCCCR) guidelines for the welfare of animals in experimental
neoplasia (2nd ed). Br J Cancer 77: 1–10
Zaffaroni M, Frapolli R, Colombo T, Fruscio R, Bombardelli E, Morazzoni
P, Riva A, D’Incalci M, Zucchetti M (2002) High-performance liquid
chromatographic assay for the determination of the novel C-Seco-taxane
derivative (IDN 5390) in mouse plasma. J Chromatogr B Analyt Technol
Biomed Life Sci 780: 93–98
IDN 5390: an oral taxane for protracted schedules
G Pratesi et al
972
British Journal of Cancer (2003) 88(6), 965–972 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s